Singular Focus, Purpose-Built Solutions: Your Partner in Life Science Insurance
Berkley Life Sciences is solely dedicated to providing premiere insurance coverage for today’s top life sciences companies.
Life Sciences Insurance Protecting Tomorrow’s Innovations
Comprehensive. Customized. Multinational. We provide property and casualty insurance products and services tailored to life sciences businesses globally. Our approach is collaborative, with underwriting, in-house claims, and risk management working in tandem to provide a complete and specialized insurance solution.
In-House Claims
From the start of the underwriting process, our in-house claims team is a true partner in your insurance experience. With extensive life science products liability claim and litigation expertise, our claims team collaborates with insureds, brokers, and our defense counsel to actively lead claims to just resolution.
The Power of Berkley
Berkley Life Sciences is one of the 55+ (re)insurance businesses worldwide that comprise the Berkley brand. Berkley is one of America’s largest commercial lines property casualty insurance providers, operating worldwide within two segments of the P&C insurance business: Insurance and Reinsurance & Monoline Excess. Each business offers expertise within an industry, product, or region.
Berkley Life Sciences is a member of W. R. Berkley Corporation, a Fortune 500 company listed on the New York Stock Exchange and is part of the S&P 500. W. R. Berkley Corporation’s insurance company subsidiaries are rated A+ (Superior), Financial Size Category XV by A.M. Best Company and A+ (Strong) by Standard & Poor’s.
Berkley’s competitive advantage lies in its long-term strategy of decentralized operations. This structure provides each Berkley business the agility of a small business—the ability to identify and respond quickly and effectively to changing market conditions and local customer needs. It provides our Berkley businesses with the strength and resources of a Fortune 500 organization as well as the financial accountability and incentives to attract and retain the highest-caliber professionals.
The Latest in Life Science
GLP-1s: Litigation, Enforcement, and Marketing Watchpoints
Previously on the blog, we focused on the regulatory and compliance risks surrounding compounded GLP‑1 products, particularly misbranding, quality concerns, and how quickly the enforcement landscape has evolved. Continuing this discussion, we broaden the lens to the developing litigation environment and additional regulatory scrutiny that can affect manufacturers, pharmacies, telehealth providers, and other stakeholders across the GLP‑1 ecosystem.
FDA’s 2026 Guidance Expands Pathway for Low-Risk Digital Health Products—But Caution Remains Essential
The new year has brought notable changes on the regulatory front for life science companies seeking to expand their portfolio of digital health products. In January 2026, the U.S. Food & Drug Administration (FDA) published updated guidance documents addressing two broad product categories: (1) low-risk digital health devices for general wellness use; and (2) clinical decision support (CDS) software.
GLP-1 Compounding: When Innovation May Mean Liability
As previously reported on our blog, the rise of compounded GLP-1 medications has sparked both excitement and concern across the healthcare and legal landscapes. As demand for weight-loss treatments increases, some pharmacies have begun offering compounded versions of popular drugs like semaglutide and tirzepatide.